BMS signs deal with Medicines Patent Pool for second-line HIV treatment
This article was originally published in Scrip
Executive Summary
The Medicines Patent Pool (MPP) and Bristol-Myers Squibb have signed a licensing agreement to increase access to the HIV medicine, atazanavir (Reyataz), in 110 developing countries. "These countries represent 88.5% of people living with HIV/AIDS in developing countries," said the MPP.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.